bioMerieux SA, 5731, VIDAS Anti-HEV IgM 25 november bioMerieux SA, 5731, VIDAS Anti-HEV IgM bioMerieux SA, 5731, VIDAS Anti-HEV IgM Following complaints from the field for false positive results when using some lots of VIDAS® Anti-HEV IgM (HEVM), bioMérieux initiated an investigation to assess product issue and identify the root-cause, While the investigation is still ongoing the followings were identified: The analysis of data retrieved from some impacted customers and tests performed internally allowed to highlight five lots (listed in Table 1) that potentially gave false positive results with patient samples. The ... Wil je het laatste nieuws in jouw mailbox ontvangen? Meld je dan aan voor de nieuwsbrief.